Advisory Alpha Llc owns $463,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Advisory Alpha LLC boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 16.0% in the second quarter, Holdings Channel.com reports. The firm owned 987 shares of the pharmaceutical company’s stock after acquiring an additional 136 shares during the period. Advisory Alpha LLC’s holdings in Vertex Pharmaceuticals were worth $463,000 at the end of the most recent reporting period.

Several other large investors have recently made changes to their positions in the business. Chase Investment Counsel Corp raised its position in Vertex Pharmaceuticals by 1.8% in the second quarter. Chase Investment Counsel Corp now owns 8,248 shares of the pharmaceutical company’s stock worth $3,866,000 after purchasing an additional 145 shares in the last quarter. EP Wealth Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 4.2% during the second quarter. EP Wealth Advisors LLC now owns 4,909 shares of the pharmaceutical company’s stock worth $2,301,000 after purchasing an additional 200 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its stake in shares of Vertex Pharmaceuticals by 10.0% during the second quarter. B. Riley Wealth Advisors Inc. now owns 10,389 shares of the pharmaceutical company’s stock valued at $4,870,000 after purchasing an additional 946 shares during the last quarter. Regal Investment Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 3.7% in the second quarter. Regal Investment Advisors LLC now owns 2,056 shares of the pharmaceutical company’s stock valued at $963,000 after purchasing an additional 73 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Vertex Pharmaceuticals by 92.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 15,942 shares of the pharmaceutical company’s stock worth $7,471,000 after buying an additional 7,647 shares in the last quarter. Institutional investors own 90.96% of the company’s shares.

Analysts set new price targets

A number of research analysts have commented on the company. Oppenheimer boosted their price objective on Vertex Pharmaceuticals from $500.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Truist Financial restated a “buy” rating and set a $550.00 target price (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Canaccord Genuity Group boosted their price target on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a research note on Wednesday, July 31st. Wells Fargo & Company boosted their price target on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a research note on Monday, June 24th. Finally, TD Cowen boosted their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Hold” and an average target price of $487.23, according to MarketBeat .

Check out our latest report on VRTX

Vertex Pharmaceuticals price performance

Shares of VRTX stock opened at $469.76 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52-week low of $341.85 and a 52-week high of $510.64. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26, and a current ratio of 2.52. The stock has a 50-day simple moving average of $478.89 and a 200-day simple moving average of $454.97. The firm has a market cap of $121.25 billion, a PE ratio of 30.48 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Your Free Report ) last released its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period last year, the company earned $3.53 EPS. The company’s revenue was up 6.1% compared to the same quarter last year. sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

Insiders place their bets

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the transaction, the chairman now owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the sale, the chairman now directly owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. The disclosure for this sale can be found here. Insiders sold a total of 31,767 shares of company stock worth $15,768,284 over the last quarter. 0.20% of shares are currently held by insiders.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, is engaged in the development and commercialization of therapies for the treatment of cystic fibrosis (CF). Market TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for age 2 years or older; SYMDEKO/SYMKEVI for people with CF of 6 years or more; ORKAMBI for patients with CF of 1 year or more; and KALYDECO for the treatment of patients 1 year of age or older who have CF with ivacaftor.

Further reading

Want to see what other hedge funds own VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Get daily news and reviews for Vertex Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.